Antikor Biopharma
Photobiotics is developing an antibody-drug conjugation platform called OptiLink which enhances an antibody fragment's ability to be chemically loaded with therapeutic drugs or imaging agents. This results in high drug loading, more favourable drug-like properties and appropriate pharmacokinetics. Our lead product is an antibody-directed phototherapy (ADP) drug, which targets tumours and is activated by a laser. Our skills lie in antibody engineering and novel drug design/synthesis. We are working with academic groups, biotech companies and pharmaceutical companies to add value to their technologies and looking for further opportunities.